Codexis to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 27th
Codexis (NASDAQ: CDXS), a provider of enzymatic solutions for therapeutics manufacturing, has scheduled its fourth quarter and fiscal year 2024 financial results announcement for February 27, 2025, after market close. The company will host a conference call and webcast at 4:30 pm Eastern Time to discuss financial results and provide a business update.
The webcast will be available on the Codexis Investor Relations website and archived for 90 days. Investors can access the live call by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A 48-hour telephone replay will be available at 877-660-6853 (domestic) or 201-612-7415 (international) with access ID #13726635.
Codexis (NASDAQ: CDXS), fornitore di soluzioni enzimatiche per la produzione di terapeutici, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'anno fiscale 2024 per il 27 febbraio 2025, dopo la chiusura del mercato. L'azienda organizzerà una conferenza telefonica e un webcast alle 16:30 ora orientale per discutere i risultati finanziari e fornire un aggiornamento aziendale.
Il webcast sarà disponibile sul sito web delle Relazioni con gli Investitori di Codexis e archiviato per 90 giorni. Gli investitori possono accedere alla chiamata in diretta componendo il numero 877-705-2976 (nazionale) o 201-689-8798 (internazionale). Una registrazione telefonica di 48 ore sarà disponibile al numero 877-660-6853 (nazionale) o 201-612-7415 (internazionale) con ID di accesso #13726635.
Codexis (NASDAQ: CDXS), proveedor de soluciones enzimáticas para la fabricación de terapias, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año fiscal 2024 para el 27 de febrero de 2025, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica y un webcast a las 4:30 pm hora del Este para discutir los resultados financieros y proporcionar una actualización empresarial.
El webcast estará disponible en el sitio web de Relaciones con Inversores de Codexis y se archivará durante 90 días. Los inversores pueden acceder a la llamada en vivo marcando el 877-705-2976 (nacional) o 201-689-8798 (internacional). Una repetición telefónica de 48 horas estará disponible al 877-660-6853 (nacional) o 201-612-7415 (internacional) con ID de acceso #13726635.
Codexis (NASDAQ: CDXS)는 치료제 제조를 위한 효소 솔루션 제공업체로서, 2024 회계연도 4분기 재무 결과 발표를 2025년 2월 27일 시장 종료 후에 예정하고 있습니다. 회사는 동부 표준시 기준 오후 4시 30분에 재무 결과를 논의하고 비즈니스 업데이트를 제공하기 위한 컨퍼런스 콜 및 웹캐스트를 개최할 예정입니다.
웹캐스트는 Codexis 투자자 관계 웹사이트에서 제공되며 90일 동안 아카이브됩니다. 투자자들은 877-705-2976(국내) 또는 201-689-8798(국제)로 전화를 걸어 생방송에 참여할 수 있습니다. 48시간 전화 재생은 877-660-6853(국내) 또는 201-612-7415(국제)에서 ID #13726635로 이용 가능합니다.
Codexis (NASDAQ: CDXS), fournisseur de solutions enzymatiques pour la fabrication de thérapeutiques, a programmé l'annonce de ses résultats financiers pour le quatrième trimestre et l'exercice 2024 pour le 27 février 2025, après la fermeture du marché. La société organisera une conférence téléphonique et un webinaire à 16h30, heure de l'Est, pour discuter des résultats financiers et fournir une mise à jour sur l'entreprise.
Le webinaire sera disponible sur le site des Relations Investisseurs de Codexis et archivé pendant 90 jours. Les investisseurs peuvent accéder à l'appel en direct en composant le 877-705-2976 (national) ou le 201-689-8798 (international). Une rediffusion téléphonique de 48 heures sera disponible au 877-660-6853 (national) ou au 201-612-7415 (international) avec l'ID d'accès #13726635.
Codexis (NASDAQ: CDXS), Anbieter von enzymatischen Lösungen für die Herstellung von Therapeutika, hat die Bekanntgabe seiner Finanzergebnisse für das vierte Quartal und das Geschäftsjahr 2024 für den 27. Februar 2025, nach Börsenschluss, angesetzt. Das Unternehmen wird um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Finanzergebnisse zu besprechen und ein Unternehmensupdate zu geben.
Der Webcast wird auf der Investor-Relations-Website von Codexis verfügbar sein und für 90 Tage archiviert. Investoren können die Live-Konferenz unter der Nummer 877-705-2976 (national) oder 201-689-8798 (international) erreichen. Eine 48-stündige Telefonwiedergabe ist unter der Nummer 877-660-6853 (national) oder 201-612-7415 (international) mit der Zugangs-ID #13726635 verfügbar.
- None.
- None.
REDWOOD CITY, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced that it will report its financial results for the fourth quarter and fiscal year 2024 on Thursday, February 27, 2025, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update.
Participants may access the live webcast on the Codexis Investor Relations website, where it will be archived for 90 days. The live call can be accessed by dialing 877-705-2976 (domestic) or 201-689-8798 (international). A telephone replay of the call will be available for 48 hours by dialing 877-660-6853 (domestic) or 201-612-7415 (international), access ID #13726635.
About Codexis
Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis™ manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor Contact
Carrie McKim
(336) 608-9706
ir@codexis.com
Media Contact
Lauren Musto
(650) 421-8205
media@codexis.com
FAQ
When will Codexis (CDXS) report Q4 and FY 2024 earnings?
How can investors access the Codexis (CDXS) Q4 2024 earnings call?
How long will the Codexis (CDXS) Q4 2024 earnings webcast be available?
What is the replay access ID for Codexis (CDXS) Q4 2024 earnings call?
